v3.26.1
Segment Information
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Information

10. Segment Information

The Company reports segment information based on the management approach, which reflects the way in which the internal reporting is used by the chief operating decision maker (CODM) to analyze performance, make decisions and allocate resources. The CODM is the Company’s Chief Executive Officer.

The Company manages its operations as a single reportable segment, which includes all activities related to the research, development, and potential future commercialization of its small molecule drug development candidates. The CODM assesses performance and decides how to allocate resources based on net loss (presented in the condensed statements of operations and comprehensive loss). The measure of segment assets is reported on the condensed balance sheets as total assets. All long-lived assets are located in the United States.

The table below shows a reconciliation of the Company’s net loss, including the significant expense categories regularly provided to and reviewed by the CODM, to the Company’s total net loss in the condensed statements of operations and comprehensive loss (in thousands):

 

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Research and development expenses:

 

 

 

 

 

 

 

 

 

 

 

 

      External research and development expenses by program:

 

 

 

 

 

 

 

 

 

 

 

 

      Dabogratinib LG-UTUC

 

$

2,512

 

 

$

—

 

 

$

4,952

 

 

$

—

 

      Dabogratinib IR NMIBC

 

 

5,397

 

 

 

2,436

 

 

 

10,645

 

 

 

3,725

 

      Dabogratinib ACH

 

 

6,577

 

 

 

2,588

 

 

 

10,886

 

 

 

6,175

 

      Dabogratinib mUC

 

 

1,270

 

 

 

1,993

 

 

 

2,884

 

 

 

5,248

 

      TYRA-430 HCC

 

 

2,147

 

 

 

2,142

 

 

 

4,193

 

 

 

4,436

 

      TYRA-200 ICC

 

 

661

 

 

 

1,329

 

 

 

1,671

 

 

 

2,794

 

      FGFR discovery

 

 

2,486

 

 

 

3,311

 

 

 

5,018

 

 

 

6,443

 

      Other development programs

 

 

1,013

 

 

 

457

 

 

 

1,862

 

 

 

971

 

      Unallocated research and development expenses:

 

 

 

 

 

 

 

 

 

 

 

 

      Personnel costs(1)

 

 

15,205

 

 

 

8,660

 

 

 

26,994

 

 

 

16,683

 

      Facilities and other costs(2)

 

 

1,929

 

 

 

1,393

 

 

 

3,562

 

 

 

2,798

 

Total research and development expenses

 

 

39,197

 

 

 

24,309

 

 

 

72,667

 

 

 

49,273

 

General and administrative expenses(3)

 

 

9,806

 

 

 

7,143

 

 

 

18,334

 

 

 

14,029

 

Interest and other income, net

 

 

(3,445

)

 

 

(3,354

)

 

 

(6,138

)

 

 

(7,057

)

Net loss

 

$

(45,558

)

 

$

(28,098

)

 

$

(84,863

)

 

$

(56,245

)

(1) Personnel costs include $5.8 million and $3.7 million of stock-based compensation for the three months ended June 30, 2026 and 2025, respectively, and $10.3 million and $7.4 million of stock-based compensation for the six months ended June 30, 2026 and 2025, respectively.

(2) Facilities and other costs consist of research consumables, facility-related costs, depreciation and costs not attributed to a specific program.

(3) General and administrative expenses consist of personnel-related expenses, including stock-based compensation, legal fees, facility-related costs, depreciation, professional and consulting fees and insurance costs.